Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Instil Bio Inc TIL

Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. Its first such program is an engineered tumor infiltrating lymphocyte (TIL), cell therapy for the treatment of cancer. It is engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR), platform. The Company's lead CoStAR-TIL product candidate, ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (Fra), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer. CAR-T and TCR-T therapies are cell products composed of T cells that have been genetically engineered to recognize a specific cancer-related antigen on the surface of tumor cells.


NDAQ:TIL - Post by User

Bullboard Posts
Post by awol1on Aug 09, 2008 1:32am
720 Views
Post# 15371173

Stockwatch- Tang acquires 1.3 mil shares

Stockwatch- Tang acquires 1.3 mil shares This might explain the activity today.  I don't think its bad at all, if anything poositive.  Comments?
Some of you who bought on the drop today could do well next week...

Ambrilia shareholder Tang acquires 1.3 million shares

2008-08-08 20:25 ET - News Release

Mr. Kevin Tang of Tang Capital reports

TANG CAPITAL PARTNERS, LP ACQUIRES SHARES OF AMBRILIA

Tang Capital Partners LP has acquired 1,304,000 shares of Ambrilia Biopharma Inc. (representing approximately 2.7 per cent of Ambrilia's issued and outstanding common shares at July 30, 2008) through the facilities of the Toronto Stock Exchange at a price per share of 11.57 cents.

After completion of the purchase of the shares, Tang Capital and an affiliated entity will own 5,264,800 common shares representing 10.8 per cent of Ambrilia's issued and outstanding common shares (as of July 30, 2008). In addition, Tang Capital and an affiliated entity own two million warrants to purchase common stock at a price per share of $1.35. These warrants expire on Oct. 29, 2010. These warrants are currently not exercisable and will not be exercisable, due to a blocker provision, so long as Tang Capital and affiliated entities own more than 9.99 per cent of Ambrilia's common stock. Tang Capital and affiliated entities may waive this blocker provision upon not less than 61 days written notice to Ambrilia.

Tang Capital acquired its securities of Ambrilia for investment purposes and may acquire or dispose of securities of Ambrilia in the future depending on market conditions and other considerations.

Tang Capital is acting jointly with the Tang Family Trust, dated Aug. 27, 2002, in connection with the securities of Ambrilia.

Bullboard Posts